In Vivo Myocardial Protection From Ischemia/Reperfusion Injury by the Peroxisome Proliferator–Activated Receptor-γ Agonist Rosiglitazone

Yue, Tian-li, Chen, Jun, Bao, Weike, Narayanan, Padma K., Bril, Antoine, Jiang, Wen, Lysko, Paul G., Gu, Juan-Li, Boyce, Rogely, Zimmerman, Dawn M., Hart, Timothy K., Buckingham, Robin E., Ohlstein, Eliot H.·2001·Circulation
DOI 10.1161/hc4601.099403

Cited by (295)

Items 201–295 of 295

  1. Variable effects of anti-diabetic drugs in animal models of myocardial ischemia and remodeling: A translational perspective for the cardiologist
    Meimei Yin, Berend Daan Westenbrink, Maxi Meissner, Wiek H. van Gilst, Rudolf A. de Boer · 2013 · International Journal of Cardiology
  2. Expression of adhesion molecules on granulocytes and monocytes following myocardial infarction in rats drinking white wine
    Nikolina Režić Mužinić, Angela Mastelić, Benjamin Benzon, Anita Markotić, Ivana Mudnić, Ivica Grković, Mia Grga, Ana Marija Milat, Nikola Ključević, Mladen Boban · 2018 · PLoS ONE
  3. Protection cellulaire par activation des récepteurs nucléaires PPAR
    Dominique Deplanque · 2004 · Therapies
  4. Cardiac Fibrosis in Diabetic Rats: Regulation and Mechanism of Activation of the PPARγ Signal Pathway
    Shu-mei Zhao · 2010 · The Chinese Journal of Physiology
  5. Study of peroxisome proliferator–activated receptor (PPAR)-γ in renal ischemia–reperfusion injury
    Ryoichi YOSHIMURA, Masahide Matsuyama, Yoshihiro Segawa, K. Tsuchida, Yoshiaki Takemoto, Katsuyuki Kuratsukuri, Yutaka Kawahito, T. Shinka, Hajime Sano, Tatsuya Nakatani · 2004 · Transplantation Proceedings
  6. The peroxisome proliferator-activated receptor gamma (PPARγ) is highly expressed in human heart ventricles
    Mohammad Reza Mehrabi, Theresia Thalhammer, Petra Haslmayer, Helmut Dietmar Glogar, Georg Maximilian Wieselthaler, Susanne Humpeler, Wolfgang Marktl, Cem Ekmekçioğlu · 2002 · Biomedicine & Pharmacotherapy
  7. Ligands of the peroxisome proliferator‐activated receptor‐γ and heart failure
    Christoph Thiemermann · 2004 · British Journal of Pharmacology
  8. Intervention of rosiglitazone on myocardium Glut-4 mRNA expression during ischemia–reperfusion injury in cardio-pulmonary bypass in dogs
    Bin Liu, Guiyou Liang, Gang Xu, Daxin Liu, Qingyong Cai, Zhenyu Gao · 2012 · Molecular and Cellular Biochemistry
  9. Pharmacogenomic, Physiological, and Biochemical Investigations on Safety and Efficacy Biomarkers Associated with the Peroxisome Proliferator-Activated Receptor-γ Activator Rosiglitazone in Rodents: A Translational Medicine Investigation
    Xinkang Wang, Xiaorong Liu, Yutian Zhan, Edward R. LaVallie, Liz Diblasio-Smith, Lisa A. Collins‐Racie, William M. Mounts, Julia Lynn Rutkowski, Xin Sheng Xu, Ilia Goltsman et al. · 2010 · Journal of Pharmacology and Experimental Therapeutics
  10. Treatment with a New Peroxisome Proliferator-Activated Receptor Gamma Agonist, Pyridinecarboxylic Acid Derivative, Increases Angiogenesis and Reduces Inflammatory Mediators in the Heart of Trypanosoma cruzi-Infected Mice
    Federico Penas, Davide Carta, Ganna Dmytrenko, Gerado A. Mirkin, Carlos Pablo Modenutti, Ágata Carolina Cevey, María Jimena Rada, María Grazia Ferlin, Marı́a Elena Sales, Nora Goren · 2017 · Frontiers in Immunology
  11. Protective Effect of Pharmacologic Preconditioning with Pioglitazone on Random-Pattern Skin Flap in Rat is Mediated by Nitric Oxide System
    Sajjad Afraz, Ali Kamran, Kasra Moazzami, Behtash Ghazi Nezami, Ahmad Reza Dehpour · 2011 · Journal of Surgical Research
  12. Pioglitazone-induced heart failure despite normal left ventricular function
    Maulik Shah, Aravindan Kolandaivelu, William Fuller Fearon · 2004 · The American Journal of Medicine
  13. Thiazolidinediones and Congestive Heart Failure
    Rujul R. Patel · 2009 · Cardiology in Review
  14. Treating the diabetic patient: appropriate care for glycemic control and cardiovascular disease risk factors.
    STUART W. ZARICH · 2003 · PubMed
  15. THE PPARγ LIGAND 15d-PGJ2 MODULATES MACROPHAGE ACTIVATION AFTER INJURY IN A MURINE TRAUMA MODEL
    M. Alexandra Monroy, Kay Opperman, Margo Pucciarelli, Smitha Yerrum, David A. Berg, John M. Daly · 2007 · Shock
  16. Effects of rosiglitazone ( PPAR γ agonist) on the myocardium in non‐hypertensive diabetic rats 罗格列酮（PPAR γ 激动剂）对非高血压糖尿病大鼠的心肌的影响
    Khodor I. Abou‐Daya, Hussein Abu Daya, Mohamad Nassereddine, Georges Joseph Nahhas, Nuha Nuwayri‐Salti · 2014 · Journal of Diabetes
  17. Therapeutic Implications of PPAR γ in Cardiovascular Diseases
    Hiroshi Hasegawa, Hiroyuki Takano, Issei Komuro · 2010 · PPAR Research
  18. Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro
    Liqun Ren, Naifeng Liu, Hong Zhi, Yingjuan Li, Yanzhi Li, Ri‐Ning Tang, Zulong Sheng · 2011 · Cardiovascular Diabetology
  19. Cardiovascular pharmacotherapy: Innovation stuck in translation
    Gerard A. P. J. M. Rongen, Kimberley Elaine Wever · 2015 · European Journal of Pharmacology
  20. Potential Cardiovascular Benefits of Insulin Sensitizers
    Biju Kunhiraman, Ali Jawa, Vivian Andrew Fonseca · 2005 · Endocrinology and Metabolism Clinics of North America
  21. Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes
    Ali Jawa, Vivian Andrew Fonseca · 2005 · Cardiology Clinics
  22. Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington’s Disease
    Marta Tomczyk, Alicja Braczko, Paulina Mierzejewska, Magdalena Podlacha, Oliwia Król, Patrycja Jabłońska, Agata Jędrzejewska, Karolina Pierzynowska, Grzegorz Węgrzyn, Ewa Maria Slominska et al. · 2022 · Cells
  23. A novel treatment strategy for glioblastoma multiforme and glioma associated seizures: Increasing glutamate uptake with PPARγ agonists
    Jared Ching, Stephanie Amiridis, Stanley S. Stylli, Andrew P. Morokoff, Terence John O'Brien, Andrew H. Kaye · 2014 · Journal of Clinical Neuroscience
  24. The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
    Demi C. Galindo, William A. Banks, Elizabeth M. Rhea · 2020 · Endocrinology Diabetes & Metabolism
  25. Systemic Hyperthermia Masks the Neuroprotective Effects of MK‐801, but not Rosiglitazone in Brain Ischaemia
    Mohsen Nategh, Kaveh Shahveisi, Alireza P. Shabanzadeh, Seyed Shahabeddin Sadr, Mohsen Parviz, Mojdeh Ghabaei · 2010 · Basic & Clinical Pharmacology & Toxicology
  26. The current approach into signaling pathways in pulmonary arterial hypertension and their implication in novel therapeutic strategies
    Magdalena Jasińska-Stroschein, Daria Orszulak–Michalak · 2014 · Pharmacological Reports
  27. Identification of potential molecular mechanisms and small molecule drugs in myocardial ischemia/reperfusion injury
    Tao Jiang, Yingcun Liu, Biao Chen, Liangyi Si · 2020 · Brazilian Journal of Medical and Biological Research
  28. Weighted Gene Co-Expression Network Analysis Reveals Key Genes and Potential Drugs in Abdominal Aortic Aneurysm
    Kejia Kan, Feng Guo, Lei Zhu, Prama Pallavi, Martin Sigl, Michael A. Keese · 2021 · Biomedicines
  29. Activation of PPARγ by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats
    Celine S. Weiss, Marco Hagenmueller, Martina Pichler, Sebastian Münz, Marco M. Ochs, Sebastian J. Buss, Raffi Bekeredjian, Hugo Albert Katus, Stefan E. Hardt · 2010 · Naunyn-Schmiedeberg s Archives of Pharmacology
  30. The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin‐angiotensin system in diet‐induced hypercholesterolemic rats
    Liqun Ren, Yingjuan Li, Yanzhi Li, Ri‐Ning Tang, Dingbo Hu, Zulong Sheng, Naifeng Liu · 2009 · Cell Biochemistry and Function
  31. Effect of rosiglitazone on rabbit model of myocardial ischemia-reperfusion injury
    Xia-qing Gao, Hua-Wei Li, Xue Ling, Ya-Hui Qiu, Yue Gao, Yang Zhang · 2013 · Asian Pacific Journal of Tropical Medicine
  32. Uremic cardiomyopathy is characterized by loss of the cardioprotective effects of insulin
    David John Semple, Sunil Bhandari, Anne‐Marie L. Seymour · 2012 · American Journal of Physiology-Renal Physiology
  33. Gene expression microarray analysis of the sciatic nerve of mice with diabetic neuropathy
    Lei Zhang, Shen Qu, Aibin Liang, Hong Jiang, Hao Wang · 2014 · International Journal of Molecular Medicine
  34. Reduced cardiotropic response to insulin in spontaneously hypertensive rats: role of peroxisome proliferator-activated receptor-γ-initiated signaling
    Haifeng Zhang, Jia Li, Rong Li, Quan‐Jiang Zhang, Heng Ma, Qiuhe Ji, Wenyi Guo, Haichang Wang, Bernard L. Lopez, Theodore A. Christopher et al. · 2008 · Journal of Hypertension
  35. Effect of Hexadecyl Azelaoyl Phosphatidylcholine on Cardiomyocyte Apoptosis in Myocardial Ischemia-Reperfusion Injury: A Hypothesis
    Limin Feng, Wennan Liu, Jianzhou Yang, Qing Wang, Shi Wu Wen · 2018 · Medical Science Monitor
  36. Stress-hyperglycemia, insulin and immunomodulation in sepsis
    Paul Ellis Marik, Murugan Raghavan · 2007 · Springer eBooks
  37. Ligands of the peroxisome proliferator‐activated receptor‐γ and heart failure
    Christoph Thiemermann · 2004 · British Journal of Pharmacology
  38. Peroxisome proliferator-activated receptor ligands in atherosclerosis
    Juan F. Viles-González, Brian G. Choi, Valentı́n Fuster, Juan J. Badimón · 2004 · Expert Opinion on Investigational Drugs
  39. Preconditioning, anesthetics, and perioperative medication
    Yon Hee Shim, Judy R. Kersten · 2008 · Best practice & research. Clinical anaesthesiology
  40. Stress-hyperglycemia, insulin and immunomodulation in sepsis
    Paul Ellis Marik, Murugan Raghavan · 2009 · Springer eBooks
  41. Rosiglitazone Does Not Show Major Hidden Cardiotoxicity in Models of Ischemia/Reperfusion but Abolishes Ischemic Preconditioning-Induced Antiarrhythmic Effects in Rats In Vivo
    Bennet Y. Weber, Gábor B. Brenner, Bernadett Kiss, Tamás G. Gergely, Nabil V. Sayour, Huimin Tian, András Makkos, Anikó Görbe, Péter Ferdinandy, Zoltán Giricz · 2022 · Pharmaceuticals
  42. Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation
    Yosuke Tanaka, Tomomi Hasegawa, Zhi Chen, Yutaka Okita, Kenji Okada · 2009 · Journal of Thoracic and Cardiovascular Surgery
  43. Thiazolidinediones: antidiabetic drugs with cardiovascular effects.
    Socrates C. Pastromas, Spyridon N. Koulouris · 2006 · PubMed
  44. Mac-1 deficiency ameliorates pressure overloaded heart failure through inhibiting macrophage polarization and activation
    Qiu‐Yue Lin, Wei-Jia Yu, Jie Bai, Wenxi Jiang, Hui‐Hua Li · 2024 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
  45. Role of Rosiglitazone as a Gastroprotective Agent Against Indomethacin-Induced Gastric Mucosal Injury in Rats
    Ashraf Taye · 2009 · Gastroenterology Research
  46. Ameliorative Role of Rosiglitazone in Hyperhomocysteinemia-Induced Experimental Cardiac Hypertrophy
    Amrit Pal Singh, Tajpreet Kaur, Randhir Singh, Nirmal Singh, Preet Mohinder Singh Bedi · 2010 · Journal of Cardiovascular Pharmacology
  47. Stress-hyperglycemia, insulin and immunomodulation in sepsis
    Paul Ellis Marik, Murugan Raghavan · 2012 · Springer eBooks
  48. Nuclear Peroxisome Proliferator-Activated Receptors and Thiazolidinediones
    Achikam Oren-Grinberg, Kyung W. Park · 2005 · International Anesthesiology Clinics
  49. A native steroid hormone derivative triggers the resolution of inflammation
    Sandra Niro, Olivier Hennebert, Robert F. Morfin · 2009 · Hormone Molecular Biology and Clinical Investigation
  50. Does Choice of Antidiabetes Therapy Influence Macrovascular Outcomes?
    STUART W. ZARICH · 2010 · Current Diabetes Reports
  51. Serum PPARγ level and PPARγ gene polymorphism as well as severity and prognosis of brain injury in patients with arteriosclotic cerebral infarction
    Weiming Wei, Xuwen Chen, Xueying Lin, Fulan Shan, Shao-Peng Lin, Qingyu Shen, Li Zhang · 2018 · Experimental and Therapeutic Medicine
  52. The role of intensive glycemic control in the management of patients who have acute myocardial infarction
    STUART W. ZARICH · 2005 · Cardiology Clinics
  53. Nuclear Receptor ERRγ Protects Against Cardiac Ischemic Injury by Suppressing GBP5 ‐Mediated Myocardial Inflammation
    Junhao Qiu, Qianji Che, Yichao Zhang, Mu Chen, Zhixing Wei, Yangjinming Bai, Tingting Zhao, Ji Yan, Zhengyang Wu, Zhen-Tao Fei et al. · 2025 · The FASEB Journal
  54. Chronic Pantoprazole Administration and Ischemia–Reperfusion Arrhythmias In Vivo in Rats—Antiarrhythmic or Arrhythmogenic?
    Hala Salah Abdel Kawy · 2015 · Cardiovascular Therapeutics
  55. Potential of glucose-lowering drugs to reduce cardiovascular events
    STUART W. ZARICH · 2009 · Current Diabetes Reports
  56. El monocito/macrófago como diana terapéutica en la aterosclerosis
    Jordi Pou, Alba Rebollo, Marta Alegret · 2007 · Clínica e Investigación en Arteriosclerosis
  57. Optimizing cardiac energy substrate metabolism: a novel therapeutic intervention for ischemic heart disease
    Jagdip S. Jaswal, Virgilio J. J. Cadete, Gary D. Lopaschuk · 2008 · Heart and Metabolism
  58. Rosiglitazone enhances neovascularization in diabetic rat ischemic hindlimb model
    Majid Khazaei, Ensieh Salehi · 2012 · Biomedical Papers
  59. Ghrelin and insulin gene expression changes in streptozotocin-induced diabetic rats after rosiglitazone pretreatment.
    S Yildirim, F. Sundler, Sema Bolkent · 2007 · PubMed
  60. Protective role of HOXB5-orchestrated mitochondrial homeostasis and mitophagy in cardiomyocytes after ischemia-reperfusion via transcriptionally activating Sirt5
    Yuanbin Li, Chuanping Feng, Hui Lin, Hui Li, Wei Zeng, Xiaoyan Dong, Zhuang Chen · 2025 · Cardiovascular Drugs and Therapy
  61. Exploration of combined effect of peroxisome proliferator activated receptor (PPAR) agonist and retinoic acid receptor (RAR) agonist on experimental models of inflammation in rats
    Manish Kakkar, Tapan Behl, Priya Nijhawan, Madhuri Grover, Dharmender Jaglan, Rajesh K. Pandey, Krishna Reddy Binjam · 2020 · Obesity Medicine
  62. Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002
    Stefan D. Anker, Ewa Anita Jankowska, Darlington Obinnaya Okonko · 2004 · Expert Opinion on Therapeutic Patents
  63. Insulin as Initial Therapy for Type 2 Diabetes is Not in the Patient’S Best Interest
    David S.H. Bell · 2004 · Endocrine Practice
  64. PPARs and Atherosclerosis
    Inès Pineda‐Torra, Jean‐Charles Fruchart, Bart Staels · 2000 · Springer eBooks
  65. Reversible Mitral and Aortic Regurgitation Due to Pioglitazone
    Sunil Kumar Kota, Prabhas Ranjan Tripathy, Siva Krishna Kota, Sruti Jammula, Sandip Kumar Panda, Kirtikumar D Modi · 2012 · Endocrine Practice
  66. Peroxisome Proliferator–Activated Receptors Ligands, Oxidative Stress, and Cardiac Fibroblast Extracellular Matrix Turnover
    Francisco J. Villarreal, Juan Asbún · 2004 · Hypertension
  67. ACSL4 Inhibition by AS-252424 Protects Visual Function by Suppressing RGC Ferroptosis After Retinal Ischemia Reperfusion Injury
    Keyu Liu, Zihao Lin, Wu Xiang, Jiayi Zhang, Xiaofeng Wu, Chenzhao Ma, Yantao Wei, Jiawei Wang, Jianqiao Li · 2026 · Molecular Neurobiology
  68. Cardiotoxicity Associated with Thiazolidinediones
    Gretchen M. Ray, Joe R. Anderson · 2010 · Elsevier eBooks
  69. Activity exerted by a benzamide derivative on injury by ischemia/reperfusion in an isolated heart model
    Rosas‐Nexticapa Marcela · 2013 · African Journal of Pharmacy and Pharmacology
  70. Xanthine Oxidase Inhibitors and Insulin Sensitizers
    Wolfram Doehner · 2005 · CRC Press eBooks
  71. Thiazolidinediones-PPAR-γ Agonists; for the treatment of Type II Diabetes Mellitus
    Somesula Swapna Rekha, Chandrashekhara. S, Vijeth Nagesh Bhat, Adhokshaja Haritas, T Dheerathi, K. N. Lakshmi Shivani · 2024 · Journal Of Advanced Zoology
  72. Liqi Huoxue dripping pills alleviate myocardial ischemia-reperfusion injury with improved mitochondrial biogenesis and reduced ferroptosis: Involvement of S100A8/A9-TLR4-ERK signaling
    Qianying Hao, Jiashu YUE, Ping Li, Qingyong He · 2026 · Phytomedicine
  73. Searching for Phytoinsulins as Cardiovascular Protector in Metabolic Syndrome
    Lele Ji, Wenjuan Xing, Ling Dong, Feng Gao · 2013 · Current Pharmaceutical Design
  74. Mechanisms of Drug-Induced Cardiovascular Toxicity: Cardiotoxicity Associated With Diabetes Medications
    J.R. Anderson, Gretchen M. Ray · 2017 · Elsevier eBooks
  75. Post-Genomic Analysis of Fatty Acid and Glucose Metabolism in Cardiovascular Disease
    José Marı́n-Garcı́a · 2014 · Elsevier eBooks
  76. Diabetes mellitus type 2, een epidemie met wereldwijde dimensies
    Antoon De Schryver, Anne Hublet, DE BACKER G · 2004 · Tijdschrift voor Geneeskunde
  77. Peroxisome proliferator activated receptors, inflammation, the vasculature and the heart
    Q. Diep, F. Amiri, E. Schiffrin · 2003 · Birkhäuser Basel eBooks
  78. Myocardial Protection — From Concepts to Clinical Practice
    Dennis V. Cokkinos · 2006 · Springer eBooks
  79. PPAR Agonism as New Pharmacological Approach to the Management of Acute Ischemic Stroke
    Elisa Benetti, Nimesh S. A. Patel, Massimo Collino · 2012 · InTech eBooks
  80. Estrategias para proteger el injerto esteatósico en el trasplante hepático
    Araní Casillas-Ramírez · 2011 · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
  81. Insulin Resistance and Acute Cardiovascular Complications
    Cees J. Tack · 2003 · Seminars in Cardiothoracic and Vascular Anesthesia
  82. L’implication du Stromal Cell-derived Factor-1 alpha dans le remodelage cardiaque une semaine après un infarctus du myocarde
    Cindy Proulx · 2008
  83. The expression receptor of peroxisome proliferator-activated receptor gamma (PPARγ) mRNA in human aorta compared to left ventricle in patients with coronary artery disease without diabetes
    Izabela Wojtkowska, Andrzej Tysarowski, Katarzyna A. Seliga, JANUSZ ALEKSANDER SIEDLECKI, Zbigniew Juraszyński, Janina Stępińska · 2012 · Biomedicine & Aging Pathology
  84. Heart failure, diabetes and the thiazolidinediones: an unfolding story
    Samy I. McFarlane, Fadi A El-Atat · 2005 · Therapy
  85. Signaling in the Cardiovascular System
    Marie Celeste Simon, Liping Liu, Bryan C. Barnhart, Regina M. Young · 2008
  86. Untersuchungen zum Einfluss des PPARgamma-Agonisten Rosiglitazon auf die Apoptose isolierter neonataler Kardiomyozyten bei Hypoxie/Reoxygenierung
    Michael Böhm · 2011
  87. Therapeutic Angiogenesis for Ischemic Vascular Disease
    Jai Pal Singh, J. Anthony Ware · 2007 · Humana Press eBooks
  88. Die Rolle endogener und intravenös verabreichter Knochenmarks- zellen im linksventrikulären Remodeling nach Myokardinfarkt
    Hans‐Joachim Gabius, Reinhold G. Erben · 2007
  89. disturbance in rat mesentery microvascular ameliorating ischemia-reperfusion-induced Potential of 3,4-dihydroxy-phenyl lactic acid for
    Toshifumi Hibi∥, Jing‐Yan Han, Yoshinori Horie, Jing‐Yu Fan, Kai Sun, Jun Guo, Soichiro Miura · 2016
  90. Tissue Repair and Cancer Control through PPARs and Their Coregulators
    Liliane Michalik, Walter Wahli · 2008 · WORLD SCIENTIFIC eBooks
  91. PPARs and atherosclerosis
    Coralie Fontaine, Caroline Duval, Olivier Barbier, Giulia Chinetti, Jean‐Charles Fruchart, Bart Staels · 2003 · Advances in molecular and cell biology
  92. Xanthine Oxidase Inhibitors and Insulin Sensitizers
    Wolfram Doehner · 2005 · CRC Press eBooks
  93. Cardiotoxicity Associated With Diabetes Medications
    J R Anderson, Gretchen M. Ray · 2025 · Elsevier eBooks
  94. Molecular mechanisms of cytoprotective effects of tanshinones in H9c2 cells
    Jin, Hyouju · 2015 · RMIT Research Repository (RMIT University Library)
  95. Fisiopatología del daño por isquemia-reperfusión en el síndrome de la torsión-dilatación gástrica
    Vı́ctor Sorribas, Manuel Gascón · 2003 · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona)